Introduction
Although it was ®rst identi®ed as an endothelial-derived relaxing factor or EDRF, nitric oxide (NO) plays a critical role in many physiological mechanisms such as macrophage phagocytosis, neuronal cell apoptosis and smooth muscle vasodilatation (Nathan and Hibbs, 1991; Palmer et al., 1987; Schmidt and Walter, 1994) . In addition to its involvement in normal cell physiology, NO also plays a pivotal role in several pathophysiological conditions. For example, NO is tumoricidal when produced by macrophages, Kuper cells, natural killer cells and endothelial cells (Curley et al., 1993) . Furthermore, NO has been shown to inhibit tumorigenicity and cancer metastasis (Juang et al., 1997) . However, inhibition of NO formation was shown in one report to block promotion of neoplastic transformation in murine ®broblasts (Mordan et al., 1993) .
NO is enzymatically produced by a family of three nitric oxide synthases: endothelial eNOS (or NOS-1), neuronal nNOS (or NOS-3) which are both constitutive and iNOS (or NOS-2) which is inducible (Stuehr, 1997) . Among NOS-2 inducers are endotoxins (such as lipopolysaccharides) and a mixture of cytokines (IL-1b, TNF-a and INF-g) (Lepoivre et al., 1989) . Other cytokines, such as IL-4, IL-8 and IL-10, inhibit NOS-2 expression (Cunha et al., 1992) .
Among the three NOS enzymes only NOS-2 has been implicated in cancer cell growth, apoptosis and metastasis. For example, several studies have shown that NOS-2 expression inhibits invasion and metastasis both in vitro and in vivo (Dong et al., 1994; Shi et al., 2000) . Furthermore, as mentioned above, NO is tumoricidal and inhibits metastasis (Curley et al., 1993; Juang et al., 1997) . Despite the importance of NOS-2 in malignancy, very little is known about its regulation by genes that either promote or suppress cancer growth. Based on its tumoricidal and antimetastatic activities NO production by NOS-2 should be suppressed by agents that promote tumor cell proliferation, survival and metastasis. Consistent with this, growth factors such as PDGF, inhibit NOS-2 expression (Schini et al., 1992) . However, very little is known about the ability of oncogenic low molecular weight GTPases such as Ras to regulate NOS-2.
The role Ras plays in mediating mitogenic signals in normal cells and inducing malignant transformation in cancer cells is well documented . For example, growth factors such as PDGF activate their receptor tyrosine kinases to recruit Ras GDP/GTP exchange factors. Once Ras is GTP-bound, it triggers several signaling pathways among which the Raf/MEK/ Erk kinase cascade is well studied and has been shown to be critical for cell proliferation. In 30% of all human cancers Ras is mutated resulting in a GTPase-de®cient, GTP-locked protein that is constitutively activated and sends a continuous proliferative signal to the nucleus (Barbacid, 1987) . In addition to the Raf/MEK/Erk cascade mentioned above, RhoA and Rac1 have been shown to be downstream eectors of Ras that are required for its ability to induce malignant transformation (Zohn et al., 1998) . Unlike Ras, RhoA and Rac1, which promote transformation, RhoB has recently been shown to suppress human tumor growth and transformation (Chen et al., 2000) . In this study we set out to test the hypothesis that Ras and RhoA suppress whereas RhoB enhances induction of NOS-2.
Results and Discussion
Activated Ras suppresses whereas dominant negative Ras enhances the ability of cytokines to stimulate NOS-2 transcription
The ability of the low molecular weight GTPase Ras to regulate cytokine induction of NOS-2 transcription was investigated in AKN-1, a liver cell line derived from normal human liver as well as in human lung adenocarcinoma cell line (A-549) where cytokine are known to induce NOS-2. First, we determined the ability of the cytokines to stimulate transcription. AKN-1 and A-549 cells were transfected with human NOS2 promoter-luciferase reporter and treated 36 h later with a mixture of cytokines (IL-1b, INF-g and TNFa) for various periods of time as described in Materials and methods. Figure 1 shows that the cytokines were able to activate NOS-2 transcriptional activity as early as 3 h after treatment. The greatest fold stimulation was observed after 6 h of cytomix treatment and by 24 h no stimulation was observed. Thus, the optimal cytomix treatment time is between 3 and 12 h.
We next evaluated the ability of Ras to regulate cytomix-stimulation of NOS-2 transcriptional activity. AKN-1 and A-549 cells were transfected with the NOS-2 promoter-luciferase reporter along with either activated Ras (Ras61L) or dominant negative Ras (Ras17N) for 36 h prior to stimulation with the cytomix for 6 h. Figure 2 shows that in AKN-1 cells cytomix stimulation of cells transfected with pcDNA3 or pSVE empty vector resulted in a 6.5 ± 7.2-fold induction of NOS-2 transcriptional activity. Transfection with Ras17N resulted in a 20-fold induction. Thus, blocking Ras signaling enhanced the ability of the cytomix to induce NOS-2 transcription. This suggested that Ras suppresses the ability of the cytomix to induce NOS-2 transcription. Figure 2 also shows that in AKN-1 cells transfected with activated Ras-61L, the cytomix ability to induce NOS-2 transcription was dramatically reduced (1.9-fold). Taken together, these results demonstrate that Ras negatively regulates the ability of the cytomix to stimulate NOS-2 transcription in AKN-1 cells. Figure 2 also shows similar results with A-549 cells. The cytomix stimulated NOS-2 transcription by 7.5-and 9.2-fold in A-549 cells transfected with pCDNA3 and pSVE empty vectors, respectively. Transfection with 17NRas enhanced (19.7-fold), whereas transfection with 61LRas suppressed (2.8 fold) cytomix-stimulation of NOS-2 ( Figure 2) . Furthermore, to document that blocking Ras signaling enhances not only cytokine-induced promoter activity but also NOS-2 protein levels, lysates from A-549 cells transfected with Ras17N prior to cytokine stimulation were immunoblotted with a NOS-2 antibody as described in Materials and methods. The Western in Figure 2 shows that Ras17N enhances the ability of the cytomix to induce NOS-2 protein levels. Therefore, the data of Figure 2 suggest that the Ras pathway antagonizes cytokine induction of NOS-2 transcription and protein levels.
The MEK/Erk pathway suppresses cytomix induction of NOS-2
The data described in Figure 2 suggests that a signal originating from Ras negatively regulate cytomix induction of NOS-2 transcription. Ras triggers several signal transduction pathways that culminate into the nucleus to regulate transcription . We next determined whether the Ras suppression of cytokine NOS-2 induction is mediated at least in part by one of the most thoroughly studied of these pathways, the mitogen activated protein kinase MEK/ Erk cascade . Figure 3a shows that in AKN-1 and A-549 cells transfected with pcDNA3 empty vector, the cytomix stimulated NOS-2 transcription by 8.2-and 7.5-fold, respectively. In contrast, in cells transfected with dominant negative Erk-DN, the cytomix-induced NOS-2 by 19.4-and 25-fold. These results demonstrate that Erk suppresses the ability of the cytomix to induce NOS-2. To con®rm this, we treated AKN-1 cells with a MEK inhibitor, PD98059, and determined the eects of this treatment on cytokine-induced stimulation of NOS-2 protein levels by immunoblotting as well as the eects of this inhibitor on NOS-2 promoter transcriptional activity. Figure 3b shows that in the absence of cytokine treatment AKN-1 cells had no detectable levels of NOS-2 protein. In contrast, treatment with the cytokine mixture resulted in induction of NOS-2 protein synthesis. Pretreatment of AKN-1 cells with PD98059 resulted in a eightfold enhancement of cytokine-stimulated NOS-2 protein expression ( Figure  3b ). Figure 3b also shows that as expected PD98059 was eective at inhibiting MEK and decreasing the levels of phospho MAPK. Furthermore, PD98059 greatly enhanced the ability of the cytokines to stimulate NOS-2 promoter transcriptional activity (Figure 3c ). Taken together, these results suggest that the ability of Ras to suppress cytomix NOS-2 induction is mediated at least in part by the MEK/Erk limb of the Ras pathway.
RhoA inhibits, Rac1 has no effect, whereas RhoB enhances cytokine-induction of NOS-2 transcription
In addition to the MEK/Erk limb of Ras-dependent signaling, two members of the Ras superfamily of GTPases, RhoA and Rac1, have also been shown to be downstream mediators of Ras-dependent proliferation and transformation (Khosravi-Far et al., 1995; Zohn et al., 1998) . To determine whether or not these two GTPases are also involved in regulating cytomixinduction of NOS-2, we carried out similar experiments to those described above. In AKN-1 and A-549 cells transfected with pcDNA3 empty vector, the cytomixstimulated NOS-2 transcription by 6.5-and 7.5-fold, respectively (Figure 4a ). In contrast, in cells transfected with wild type RhoA, cytomix activation of NOS-2 was only 3.1-and 2.4-fold. Consistent with this, activated RhoA (RhoA63L) inhibited the ability of the cytomix to induce NOS-2 down to 2.3-and 2.6-fold. Similar experiments with the closely related family member, Rac1, demonstrated that wild-type Rac1 and activated Rac1 had very little aect on the ability of the cytomix to induce NOS-2 transcription (Figure 4b) . Thus, the ability of Ras and RhoA to suppress cytomix induction of NOS-2 transcription is speci®c.
To further investigate the speci®city of the suppression of cytomix NOS-2 induction by low molecular weight GTPases, we next analysed the eects of the closely related RhoA family member, RhoB. Figure 5 shows that in control, empty vector (pCMV) transfected AKN-1 and A-549 cells the cytomix induced NOS-2 by 5.3-and 5.7-fold, respectively. In contrast, in wild type RhoB, the cytomix induced NOS-2 by 14.7-and 16.9-fold. Similarly, in activated RhoB cells, the cytomix activated NOS-2 by 15.6-and 15.8-fold. Thus, RhoB enhanced the ability of the cytomix to induce NOS-2 by 300%. Furthermore, although RhoA and RhoB are 86% identical in amino acid sequence, RhoA suppresses whereas RhoB enhances cytomix-induced NOS-2 transcription.
The data described so far demonstrate that Ras and RhoA suppress whereas RhoB enhances cytokineinduced transcription of NOS-2. To determine if Ras and RhoA suppress NOS-2 transcription independently or involve the same pathway, we co-transfected A-549 Figure 2 Activated Ras 61L suppresses whereas dominant negative Ras 17N enhances cytokine activation of NOS-2 expression. Human liver AKN-1 cells and human lung cancer A-549 cells were transfected with Luc-NOS-2 promoter-reporter along with activated Ras 61L (pSVE as control), or dominant negative Ras17N (pcDNA3 as empty vector), then treated with the cytokines as described in Materials and methods. The NOS-2 promoter activity was determined as described under the legend of Figure 1 . Values are average (+s.e.) of ®ve independent experiments. The NOS-2 Western blot shows data from A-549 cells transfected with either pcDNA3 empty vector or dominant negative Ras17N prior to cytomix stimulation as described in Materials and methods cells with activated Ras61L and dominant negative RhoA19N. As expected we found that activated Ras suppressed whereas dominant negative RhoA enhanced cytokine activation of NOS-2 transcription. However, when Ras61L and RhoA19N were co-transfected, the ability of the cytokines to induce NOS-2 transcription was enhanced (data not shown). This suggest that Ras and RhoA are involved in the same pathway and that dominant negative RhoA19N blocks the ability of Ras61L to activate endogenous RhoA.
The ability of NO and NOS-2 to suppress tumor proliferation, induce apoptosis and inhibit metastasis of cancer cells may be a critical mechanism to protect cells from becoming cancerous and invading surrounding and distant tissues (Curley et al., 1993; Dong et al., 1994; Juang et al., 1997; Mordan et al., 1993; Shi et al., 2000) . Indeed, recently it has been shown that NOS-2 is required for inhibition of metastasis (Wang et al., 2001) . This mechanism may go awry or may no longer be operational when the balance between NOS-2 inducers and inhibitors is tipped towards a downregulation of NOS-2. This may occur, for example, in human cancer cells which express certain oncogenes. In this manuscript we provide evidence to support this hypothesis. We show that an oncogenic constitutively activated form of Ras suppresses whereas a dominant negative form of Ras enhances the ability of cytokines to induce NOS-2 in AKN-1, an epithelial cell line derived from normal human liver and the human lung adenocarcinoma cell line, A-549. Furthermore, we have also demonstrated that in the presence of dominant negative Ras, cytokines induce more NOS-2 at the protein level. The notion that the Ras pathway downregulates NOS-2 is further strengthened by the fact that dominant negative Erk2, a downstream eector of Ras, mimicked the eect of dominant negative Ras on NOS-2. Furthermore, an inhibitor of MEK, PD98059, enhanced the ability of cytokine induced NOS-2 protein expression. While our studies in AKN-1 and A-549 cells show that the Ras/Erk pathway suppresses, studies in rat cardiac myocytes and rat primary astrocytes suggested that the Ras/Erk pathway enhances NOS-2 expression (Pahan et al., 1998 (Pahan et al., , 2000 Singh et al., 1996) . However, the agents used to induce NOS-2 were dierent. While we used a mixture of three cytokines (IL-1b, INF-g and TNF-a), the studies in cardiac myocytes and primary astrocytes used LPS, ceramide or okadaic acid either alone or in combination with one or two cytokines. Therefore, further studies are required to determine whether the role of the Ras/Erk pathway as a mediator or an antagonist of NOS-2 expression depends on the agents used to stimulate NOS-2 as well as the tissue and species of origin of the cell lines used. Furthermore, it would also be important to determine whether the Ras/ MEK pathway suppresses the ability of single cytokines to stimulate NOS-2 transcription. In AKN-1 cells, we found that only IFN-g is capable of stimulate NOS-2 (data not shown).
Our studies also showed that RhoA suppressed the ability of cytokines to induce NOS-2 in AKN-1 and A-549 cells. This is consistent with our previous studies that show that an inhibitor of RhoA geranylgeranylation, GGTI-298, enhanced the ability of IL-1b to stimulate NOS-2 in smooth muscle cells (Finder et al., 1997) . This is also consistent with a recent study in smooth muscle cells where C 3 exozyme, an inhibitor of Rho proteins, was shown to enhance IL-1b induction of NOS-2 (Muniyappa et al., 2000) . However, because C3 exozyme inhibits several Rho proteins, it is not possible to identify from this study (Muniyappa et al., 2000) which Rho is involved. Our present studies implicate speci®cally RhoA and this eect is selective since a related family member, Rac1, did not aect cytokine induction of NOS-2. More important is that a closely related family member, RhoB, which has 86% amino acid identity with RhoA, enhanced the ability of cytokines to induce NOS-2. The fact that Ras and RhoA suppressed whereas RhoB enhanced NOS-2 induction is consistent with the tumor promoting activities of Ras and RhoA Khosravi-Far et al., 1995; Zohn et al., 1998) and the fact that RhoB suppresses tumor growth and induces apoptosis of human cancer cells in vitro and in vivo (Chen et al., 2000) . Presently, we are investigating whether the ability of Ras and RhoA to downregulate and RhoB to upregulate NOS-2 induction is related to their oncogenic and tumor suppressive activities, respectively. Taken together, our results demonstrate for the ®rst time that oncogenes such as Ras and RhoA inhibit whereas genes with tumor suppressor activity such as RhoB enhance NOS-2 induction. An important challenge ahead is to determine the pathways connecting Ras, RhoA and RhoB to NOS-2 transcriptional activation.
Materials and methods

Cells and materials
AKN-1, a liver epithelial cell line was derived from normal human liver as described previously (Nussler et al., 1999) . AKN-1 cells were maintained in Dubelcco's Williams Medium M supplemented with 10% fetal bovine serum, Insulin 100 mg/ml, penicillin/streptomycin and glutamine. The human lung adenocarcinoma cell line, A-549, was purchased from ATCC (Rockville, MD, USA) and was grown in Ham's F12K nutrient mix supplemented with 10% FBS. Activated H-Ras 61L, dominant negative Ras17N, RhoA, RhoA63L, Rac1 and Rac1151 were a kind gift from Dr Channing Der (University of North Carolina) (Khosravi-Far et al., 1995) . RhoB-WT and activated RhoB were a kind gift from Dr. Alan Hall (Baron et al., 2000) . The NOS-2 full length promoter was described previously (de Vera et al., 1996) . PD98059 was purchased from Calbiochem.
NOS-2 promoter transcriptional activity determination
Transfection were performed with the calcium/phosphate protocol as previously described (Sambrook et al., 1989) . Brie¯y, cells were plated in 60 mm plates, at 75% con¯uency the day before the transfection. Luc-NOS-2 promoter plasmid was used at 6 ± 8 mg per plate, whereas all the other plasmids were used at 0.5 ± 1.0 mg per plate. 12 ± 15 h after transfection, medium was replaced by fresh media and cells grown for 24 h. Then the cytokines were diluted in fresh medium and added to cells for 6 h. The cytokine concentrations were for human TNFa 10 ng/ml, human IL-1b 1 ng/ml and human IFNg 100 ng/ml. After cytokines treatment cells were washed two times with PBS and lyzed in Promega Passive Lysis Buer 56. Aliquots of the whole lysates were then used to measure the luciferase and the b-galactosidase activities. The NOS-2 promoter speci®c activity is determined from the ratios of Luc/b-gal. All experiments were performed in duplicate and the averages of several (see Figure legends) independent experiments are reported. The levels of NOS-2 activation was determined by calculating the ratio of the Luc/ bGal in the presence of cytomix for each condition, divided by the value obtained with the empty vector control without the presence of cytomix.
Treatment with MEK inhibitor and Western immunoblotting
AKN-1 cells were plated in Dubelcco's Williams' Medium M supplemented with 10% fetal bovine serum, Insulin 100 mg/ ml, penicillin/streptomycin and glutamine on day 1. On day 2, cells were treated with either DMSO as a vehicle or PD98059 (50 mM) for 15 min, before treating for 8 h with the cytomix. The cells were then harvested and lyzed in lysis buer (30 mM HEPES pH 7.5, 1% Triton X-100, 10% Glycerol, 10 mM NaCl, 5 mM MgCl 2 , 25 mM NaF, 1 mM EGTA, 10 mg/ml trypsin inhibitor, 25 mg/ml leupeptin, 10 mg/ ml aprotinin and 2 mM phenyl methul sulfonyl¯uoride). The lysates were submitted to freeze/thaw cycles, then 50 mg of proteins were loaded on 7.5% SDS ± PAGE, transferred to nitrocellulose membrane and immunoblotted with human NOS-2 antibody (Pharmingen) as described previously (Finder et al., 1997) .
For determining the eects of dominant negative Ras17N on the protein levels of NOS-2, A-549 cells were plated in 6-well plates and transfected the following day with pcDNA3 (6 mg) or Ras17N (6 mg) (in 0.5 ml of serun free DMEM medium) and 30 ml of Gene Porter transfection reagent (Gene Therapy Systems) diluted in 0.5 ml serum free DMEM medium. Five hours later, 0.5 ml of 20% FBS DMEM medium was added to the cells. Medium was replaced by fresh medium (24 h later) containing vehicle or cytokines. Cells were harvested and processed for SDS ± PAGE and immunoblotting with anti-NOS-2 antibody as described above.
Abbreviations NO, nitric oxide; NOS, nitric oxide synthase; INF, interferon; IL, interleukin; TNF, tumor necrosis factor; LPS, lypopolysaccharides; MAPK, mitogen-activated protein kinase.
